I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb (BMY) closed at $59.12, down 3.32% for the week. The S&P 500 rose 1.15% over the same period, so BMY lagged the benchmark by about 4.47 percentage points. The share followed a choppy path: it gapped lower on Monday (5 Oct) and hit the week’s low of $58.33, rebounded to $59.58-$59.70 from Tuesday to Thursday, then slipped back to $59.12 on Friday. The share spent the week below the prior close of $61.15.
The Week
Bristol Myers Squibb (BMY) closed at $59.12, down 3.32% for the week. The S&P 500 rose 1.15% over the same period, so BMY lagged the benchmark by about 4.47 percentage points. The share followed a choppy path: it gapped lower on Monday (5 Oct) and hit the week’s low of $58.33, rebounded to $59.58-$59.70 from Tuesday to Thursday, then slipped back to $59.12 on Friday. The share spent the week below the prior close of $61.15.
Key Events
Pipeline risk and a key clinical readout dominated the week. On Monday, Leerink downgraded Bristol Myers and flagged R&D pipeline risks, with the stock moving down 3.56% that day. On Thursday, the company said its ZENBEXUS combination cut the risk of multiple myeloma progression by 51% in the Phase 3 EXCALIBER-RRMM trial, marking a notable advance in blood cancer treatment. Immunome also restructured its deal with Bristol Myers, gaining key patent rights. MRA Advisory Group reduced its position during the week, though that shift had limited impact relative to company-specific developments.
Analyst Ratings
Across 29 brokers covering Bristol Myers, 6 rate it buy, 4 overweight, 17 hold, 1 sell, and 1 has no opinion, making 10 buy or overweight and 1 sell. The consensus rating is hold, with a consensus target of $65.71, implying about 11.1% upside from the current price. Targets range from $41.00 to $82.00, pointing to wide dispersion. Among 203 pharmaceutical stocks, the ratings rank is 2.
The Week Ahead
The macro calendar is busy: NFIB small business optimism and existing home sales are due on Tuesday (13 Oct), followed by US CPI and core CPI on Wednesday (14 Oct). Inflation prints will influence the rate path directly. On the company side, Bristol Myers reports fiscal Q3 2026 earnings before market open on 29 Oct, with estimates at $1.1501 EPS and roughly $12.7b revenue; further ZENBEXUS commentary could emerge there.
In Short
Bristol Myers spent the week caught between pipeline concerns and a positive clinical update. The share shook off a downgrade and slipped on the week, yet the ratings mix still leans neutral-to-positive, with the consensus target above spot. Valuation sits at about 13x P/E, 5.41x P/B, and a 4.26% dividend yield. In the latest session, large-lot money was a net seller while small and medium money were net buyers. What matters next is whether inflation data triggers broader sector rotation, and whether the late-October earnings can validate the commercial promise of ZENBEXUS and the wider pipeline.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.